CEL-SCI Announces Closing of $10 Million Public Offering
CVM(CVM) VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of $10 million public offering.
August 29, 2025Offering
Read more →CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results
CVMVIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports fiscal third quarter 2025 financial results.
August 14, 2025Earnings
Read more →CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline
CVMVIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia.
August 13, 2025Regulatory
Read more →FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients
CVMVIENNA, Va.--(BUSINESS WIRE)---- $CVM #HNSCC--FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine.
June 18, 2025Clinical
Read more →Reported Earlier, CEL-SCI Prices $5M Public Offering At $2.50/Share To Advance Multikine Cancer Immunotherapy Development
CVMMay 22, 2025
Read more →CEL-SCI Announces Proposed Public Offering; No Size Or Amount Disclosed
CVMMay 21, 2025
Read more →CEL-SCI Completes Breakthrough Medicine Designation Application For Multikine For Submission To Saudi Food And Drug Authority
CVMMay 21, 2025
Read more →CEL-SCI Corp. Board Approves 1-For-30 Stock Combination, Effective May 20, 2025
CVMMay 19, 2025
Read more →CEL-SCI Q2 EPS $(0.08) Up From $(0.14) YoY
CVMMay 15, 2025
Read more →CEL-SCI Met With Saudi Food And Drug Authority, Says Is Preparing To Submit A Regulatory Filing For The Approval Of Multikine As A Neoadjuvant Treatment Of Newly Diagnosed Previously Untreated Locally Advanced Head And Neck Cancer
CVMApril 23, 2025
Read more →CEL-SCI Announces Study Published In 'Cancer Cell' Confirms Pre-Surgical Tumor Response In Head And Neck Cancer Patients Treated With Its Multikine Improves Overall Survival, Supporting Early Regulatory Approval As A Neoadjuvant Treatment For Locally Adv
CVMApril 8, 2025
Read more →CEL-SCI Announces Publication From Prior 3 Study Of Multikine In Journal 'Pathology and Oncology Research'
CVMMarch 24, 2025
Read more →CEL-SCI Announces Pricing Of $2.56M Best-Efforts Offering Of 16M Shares Of Common Stock
CVMMarch 17, 2025
Read more →CEL-SCI Announces That A Third-Party Study Published In Jama Oncology Titled Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-stratified Chemoradiation Therapy In HPV-Negative Head And Neck Cancer: The DEPEND Phase 2 Non-Randomized Clinical Tr
CVMMarch 14, 2025
Read more →Cel-Sci shares are trading higher after the company announced it is in the final stages of its 212-patient confirmatory registration study of Multikine.
CVMFebruary 20, 2025
Read more →CEL-SCI Announces Final Stages For 212-Patient Confirmatory Registration Study Of Multikine In Advanced Head And Neck Cancer To Confirm Phase 3 Efficacy And Safety Results
CVMFebruary 20, 2025
Read more →CEL-SCI Highlights Multikine's 73% 5-Year Survival Benefit In Low PD-L1 Head And Neck Cancer Patients; New Phase 3 Confirmatory Trial Planned With Ergomed As CRO Partner; Accelerated Approval Possible In 2026 Based On Tumor Response Data
CVMFebruary 18, 2025
Read more →CEL-SCI Q4 EPS $(0.09) Beats $(0.11) Estimate
CVMJanuary 14, 2025
Read more →CEL-SCI Q2 2024 GAAP EPS $(0.28) Misses $(0.14) Estimate
CVMMay 16, 2024
Read more →